Optic nerve gliomas in adults: a SEER-based study
Introduction: Optic nerve gliomas (ONGs) are uncommon tumors of the central nervous system in adults. The aim of this study was to define their characteristics, prognostic factors, and the impacts of adjuvant radiotherapy (RT) and chemotherapy on outcomes. Methods: Adult patients (age ≥18 years) wit...
Gespeichert in:
Veröffentlicht in: | All life (Online) 2022-12, Vol.15 (1), p.262-269 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction: Optic nerve gliomas (ONGs) are uncommon tumors of the central nervous system in adults. The aim of this study was to define their characteristics, prognostic factors, and the impacts of adjuvant radiotherapy (RT) and chemotherapy on outcomes. Methods: Adult patients (age ≥18 years) with ONGs from the Surveillance, Epidemiology, and End Results (SEER) database were included. Univariate and multivariate Cox regression models were utilized to analyze the factors associated with survival. Kaplan-Meier method was used to evaluate the impacts of adjuvant therapies on overall survival (OS). Results: A total of 179 adult patients diagnosed with ONGs were identified between 1991 and 2016, with a median follow-up period of 64.0 months. Multivariate analysis showed age at diagnosis, tumor grade, adjuvant chemotherapy were significant factors for OS. The employment of adjuvant RT or chemotherapy significantly shortened OS time in the low-grade group and could not prolong OS time in the high-grade group. Conclusions This is the largest retrospective study of adult ONGs up to date. The overall prognosis of high-grade ONGs in adult patients is still poor despite multi-modality treatments. Adjuvant RT or chemotherapy should be applied cautiously before full clinical evaluation in adult patients with low-grade ONGs. |
---|---|
ISSN: | 2689-5293 2689-5307 |
DOI: | 10.1080/26895293.2022.2046180 |